These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32296640)

  • 1. Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer.
    Shah C; Hong YR; Bishnoi R; Ali A; Skelton WP; Dang LH; Huo J; Dang NH
    Front Oncol; 2020; 10():405. PubMed ID: 32296640
    [No Abstract]   [Full Text] [Related]  

  • 2. Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study.
    Bishnoi R; Hong YR; Shah C; Ali A; Skelton WP; Huo J; Dang NH; Dang LH
    Cancer Med; 2019 Jul; 8(8):3918-3927. PubMed ID: 31124302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
    Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
    Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
    Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multi-Center Retrospective Analysis Examining the Effect of Dipeptidyl Peptidase-4 Inhibitors on Progression-Free Survival in Patients With Prostate Cancer.
    Pan K; Skelton WP; Elzeneini M; Nguyen TC; Franke AJ; Ali A; Bishnoi R; Dang L; Dang NH; Kish J
    Cureus; 2021 Apr; 13(4):e14712. PubMed ID: 34055551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of DPP4 inhibitors on the levels of plasma catecholamines and their metabolites in patients with type 2 diabetes.
    Kim TH; Lee K; Park IB; Choi CS; Ahn TH; Lee DH
    Diabetes Res Clin Pract; 2019 Oct; 156():107832. PubMed ID: 31513823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19.
    Zhou JH; Wu B; Wang WX; Lei F; Cheng X; Qin JJ; Cai JJ; Zhang XJ; Zhou F; Liu YM; Li HM; Zhu LH; She ZG; Zhang X; Yang J; Li HL
    World J Clin Cases; 2020 Nov; 8(22):5576-5588. PubMed ID: 33344548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
    Dombrowski S; Kostev K; Jacob L
    Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bullous Pemphigoid Associated with Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Type 2 Diabetes: A Multicenter Study in Istanbul.
    Ugurer E; Ozkur E; Altunay IK; Sen EC; Aksu AEK; Ozcan I; Altuntas Y; Gurel MS
    Sisli Etfal Hastan Tip Bul; 2022; 56(3):375-380. PubMed ID: 36304224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.
    Liu X; Men P; Wang Y; Zhai S; Liu G
    Lipids Health Dis; 2016 Nov; 15(1):204. PubMed ID: 27881129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study.
    Chung YR; Ha KH; Kim HC; Park SJ; Lee K; Kim DJ
    Diabetes Metab J; 2019 Oct; 43(5):640-648. PubMed ID: 30877707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
    Cho YY; Cho SI
    Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
    Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
    Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study.
    Lin YH; Huang YY; Wu YL; Lin CW; Chen PC; Chang CJ; Hsieh SH; Sun JH; Chen ST; Lin CH
    Diabetol Metab Syndr; 2018; 10():75. PubMed ID: 30349614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitor use and mortality in COVID-19 patients with diabetes mellitus: an updated systematic review and meta-analysis.
    Pal R; Banerjee M; Mukherjee S; Bhogal RS; Kaur A; Bhadada SK
    Ther Adv Endocrinol Metab; 2021; 12():2042018821996482. PubMed ID: 33680425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
    Richards KA; Liou JI; Cryns VL; Downs TM; Abel EJ; Jarrard DF
    J Urol; 2018 Dec; 200(6):1256-1263. PubMed ID: 29940252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors
    Roberto G; Girardi A; Barone-Adesi F; Pecere A; Ientile V; Bartolini C; Da Cas R; Spila-Alegiani S; Ferrajolo C; Francesconi P; Trifirò G; Poluzzi E; Baccetti F; Gini R
    Front Pharmacol; 2022; 13():871052. PubMed ID: 35707398
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.